Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

23 Jan, 2024, 22:01 GMT

Share this article

Share toX

Share this article

Share toX

The CAR-T cell therapy market is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments. The market offers several opportunities for growth, including the development of novel CAR-T cell therapies, the expansion of the therapy to other types of cancer, and the increasing adoption of CAR-T cell therapy in emerging markets.

LAS VEGAS, Jan. 23, 2024 /PRNewswire/ -- DelveInsight's CAR T-Cell Therapy Market Insights report includes a comprehensive understanding of current treatment practices, emerging CAR T-cell therapies, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the CAR T-Cell Therapy Market Report

  • According to DelveInsight's analysis, the market size for CAR T-cell therapy across the 7MM is expected to grow with a significant CAGR by 2032.
  • Leading CAR T-cell therapy companies such as CytoAgents, Inc., Genentech, Inc., Incyte Corporation, Caribou Biosciences, Inc., Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, LLC, SecuraBio, ImmPACT Bio, A2 Biotherapeutics Inc., Gracell Biopharmaceuticals, Inc., Wugen, Inc., Sana Biotechnology, Oncternal Therapeutics, Inc, Vor Biopharma, CARsgen Therapeutics Co., Ltd., Autolus Limited, Arcellx, Inc., Kite, Novartis, Lyell Immunopharma, Inc., ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Inc., Precigen, Inc, AffyImmune Therapeutics, Inc., 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech USA Inc, Miltenyi Biomedicine GmbH, Beam Therapeutics Inc., and others are developing novel CAR T-cell therapies that can be available in the CAR T-cell therapy market in the coming years.
  • The promising CAR T-cell therapies in the pipeline include CTO1681 10, Cevostamab, Itacitinib, CB-012, CHM-1101, ALLO-605, KYV-101, CD4CAR, SYNCAR-001, JNJ-90009530, Duvelisib, IMPT-514, A2B694, GC012F, WU-CART-007, SC291, ONCT-808, VCAR33, CT041, AUTO1, CART-ddBCMA, PHE885, LYL797, IMPT-314, GPC2, P-MUC1C-ALLO1, PRGN-3005 UltraCAR-T cells, AIC100, SC-DARIC33, TAK-981, Descartes 08, DSG3-CAART, LB1908, MB-CART2019.1, BEAM-201, and others.
  • Among all the CAR-T therapies used in the treatment of DLBCL, YESCARTA demonstrated excellent results. Therefore, it will be interesting to know the highest peak share generator in other CAR-T-cell therapies, including KYMRIAH and BREYANZI. Currently, YESCARTA captured the highest patient share among all CAR-T therapies.
  • Clinical studies have shown that CAR-T therapy can achieve high response rates, with some studies reporting response rates of up to 80% in patients with multiple myeloma. CAR-T therapy has the potential to induce long-term remission in some patients with multiple myeloma, which may translate into improved overall survival.
  • CAR-T therapy holds great promise for the treatment of MCL, and ongoing clinical studies are exploring its potential in this patient population. However, more research is needed to fully understand its long-term safety and efficacy.

Discover which therapies are expected to grab the major CAR T-cell therapy market share @ CAR T-Cell Therapy Market Report

CAR T-Cell Therapy Overview

CAR T-cells are formed by merging a chosen single-chain variable fragment from a particular monoclonal antibody with one or more intracellular signaling domains of T-cell receptors. Essentially, a CAR integrates antigen-binding elements, typically a single-chain variable fragment (scFv) sourced from antibody variable domains, with signaling domains from the TCR chain and supplementary costimulatory domains derived from receptors like CD28, OX40, and CD137.

From the inception of CARs in 1989, CAR T-cells have undergone categorization into four generations based on their intracellular domain structure. The first generation involved the incorporation of the ζ (zeta) chain from the complex TCR/CD3 (CD3ζ). Second-generation CARs are distinguished by a dual signaling mechanism for T-cell activation. This involves triggering one signal through antigen recognition and another through a co-stimulatory molecule, like CD28/B7, which facilitates IL-2 synthesis to ensure full T-cell activation and prevent apoptosis.

CAR T-Cell Therapy Epidemiology Segmentation

The CAR T-cell therapy epidemiology section provides insights into the historical and current CAR T-cell therapy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The CAR T-cell therapy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Incident Cases of Selected Cancer Indications
  • Line-wise Treated Cases of Selected Cancer Indications

CAR T-Cell Therapy Treatment Market 

CAR T-cell therapy has undergone swift advancements in cancer treatment, with the US FDA approving six therapies since 2017. These treatments are authorized for addressing blood cancers such as lymphomas, certain types of leukemia, and, most recently, multiple myeloma. The initial approval, KYMRIAH in August 2017, targeted ALL. Presently, CAR T-cell therapies are tailored to the unique characteristics of each patient. 

YESCARTA (axicabtagene ciloleucel) is a genetically modified autologous T-cell immunotherapy with CD19-directed action. It is designated for the treatment of adult patients experiencing relapsed or refractory large B-cell lymphoma after undergoing two or more rounds of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL originating from follicular lymphoma. The FDA initially approved YESCARTA on October 18, 2017, followed by approval from the EMA on August 23, 2018.

Following the YESCARTA approval in DLBCL in 2017, the US FDA authorized KYMRIAH (tisagenlecleucel) in May 2018 for treating adult patients with R/R large B-cell lymphoma who had undergone two or more lines of systemic therapy. This encompassed DLBCL, high-grade B-cell lymphoma, and DLBCL resulting from follicular lymphoma. Subsequently, in February 2021, Bristol Myers Squibb disclosed that the US FDA had endorsed BREYANZI (lisocabtagene maraleucel) for adult patients with R/R large B-cell lymphoma (LBCL). This marked the third CAR T-cell therapy approved for DLBCL.

Since November 2023, only two CAR T-cell therapies have gained approval in the field of multiple myeloma. The first FDA-approved CAR T cell therapy for adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, involving specific medications, was ABECMA (idecabtagene vicleucel), a joint venture by Bristol Myers Squibb and bluebird bio, sanctioned in 2021. Subsequently, in February 2022, the FDA approved CARVYKTI (ciltacabtagene autoleucel) developed by Janssen/Legend Biotech.

To know more about CAR T-cell therapy, visit @ CAR T-Cell Therapies

Pipeline CAR T-Cell Therapies and Key Companies

  • CTO1681 10: CytoAgents, Inc.
  • Cevostamab: Genentech, Inc.
  • Itacitinib: Incyte Corporation
  • CB-012: Caribou Biosciences, Inc.
  • CHM-1101: Chimeric Therapeutics
  • ALLO-605: Allogene Therapeutics
  • KYV-101: Kyverna Therapeutics
  • CD4CAR: iCell Gene Therapeutics
  • SYNCAR-001: Synthekine
  • JNJ-90009530: Janssen Research & Development, LLC
  • Duvelisib: SecuraBio
  • IMPT-514: ImmPACT Bio
  • A2B694: A2 Biotherapeutics Inc.
  • GC012F: Gracell Biopharmaceuticals, Inc.
  • WU-CART-007: Wugen, Inc.
  • SC291: Sana Biotechnology
  • ONCT-808: Oncternal Therapeutics, Inc
  • VCAR33: Vor Biopharma
  • CT041: CARsgen Therapeutics Co., Ltd.
  • AUTO1: Autolus Limited
  • CART-ddBCMA: Arcellx, Inc./Kite
  • PHE885: Novartis
  • LYL797: Lyell Immunopharma, Inc.
  • IMPT-314: ImmPACT Bio
  • GPC2: Tmunity Therapeutics
  • P-MUC1C-ALLO1: Poseida Therapeutics, Inc.
  • PRGN-3005 UltraCAR-T cells: Precigen, Inc
  • AIC100: AffyImmune Therapeutics, Inc.
  • SC-DARIC33: 2seventy bio
  • TAK-981: Takeda
  • Descartes 08: Cartesian Therapeutics
  • DSG3-CAART: Cabaletta Bio
  • LB1908: Legend Biotech USA Inc
  • MB-CART2019.1: Miltenyi Biomedicine GmbH
  • BEAM-201: Beam Therapeutics Inc.

Learn more about the FDA-approved CAR T-cell therapies @ CAR T-Cell Therapy Treatment Drugs

CAR T-Cell Therapy Market Dynamics

The dynamics of the CAR T-cell therapy market are expected to change in the coming years. CAR-T therapy holds great promise for treating various types of cancer, as ongoing clinical studies investigate its potential. Numerous companies are actively developing allogeneic CAR-Ts and bi-specific CAR-Ts specifically for DLBCL, multiple myeloma, and other forms of cancer.

Furthermore, many potential therapies are being investigated for the treatment of various cancers, and it is safe to predict that the treatment space will significantly impact the CAR T-cell therapy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the CAR T-cell therapy market in the 7MM.

However several factors may impede the growth of the CAR T-cell therapy market. The growth of the CAR T-cell therapy medicine market has been impeded due to a shortage of trained professionals to administer the treatment in certain developing and underdeveloped countries. Additionally, the high cost of the therapy has also acted as a hindrance to the CAR T-cell therapy market's expansion.

Moreover, CAR T-cell therapy treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the CAR T-cell therapy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the CAR T-cell therapy market growth.

CAR T-Cell Therapy Market Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key CAR T-Cell Therapy Companies

CytoAgents, Inc., Genentech, Inc., Incyte Corporation, Caribou Biosciences, Inc., Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, LLC, SecuraBio, ImmPACT Bio, A2 Biotherapeutics Inc., Gracell Biopharmaceuticals, Inc., Wugen, Inc., Sana Biotechnology, Oncternal Therapeutics, Inc, Vor Biopharma, CARsgen Therapeutics Co., Ltd., Autolus Limited, Arcellx, Inc., Kite, Novartis, Lyell Immunopharma, Inc., ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Inc., Precigen, Inc, AffyImmune Therapeutics, Inc., 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech USA Inc, Miltenyi Biomedicine GmbH, Beam Therapeutics Inc., and others

Key Pipeline CAR T-Cell Therapies

CTO1681 10, Cevostamab, Itacitinib, CB-012, CHM-1101, ALLO-605, KYV-101, CD4CAR, SYNCAR-001, JNJ-90009530, Duvelisib, IMPT-514, A2B694, GC012F, WU-CART-007, SC291, ONCT-808, VCAR33, CT041, AUTO1, CART-ddBCMA, PHE885, LYL797, IMPT-314, GPC2, P-MUC1C-ALLO1, PRGN-3005 UltraCAR-T cells, AIC100, SC-DARIC33, TAK-981, Descartes 08, DSG3-CAART, LB1908, MB-CART2019.1, BEAM-201, and others

Scope of the CAR T-Cell Therapy Market Report

  • Therapeutic Assessment: CAR T-Cell Therapy current marketed and emerging therapies
  • CAR T-Cell Therapy Market Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy Market Access and Reimbursement

Discover more about CAR T-cell therapy drugs in development @ CAR T-Cell Therapy Clinical Trials

Table of Contents

1.

CAR T-Cell Therapy Key Insights

2.

CAR T-Cell Therapy Report Introduction

3.

CAR T-Cell Therapy Overview at a Glance

4.

CAR T-Cell Therapy Executive Summary

5

CAR T-Cell Therapy Key Events

6

Epidemiology and Market Forecast Methodology

6.

Disease Background and Overview

7.

CAR T-Cell Therapy Treatment and Management

8.

CAR T-Cell Therapy Guidelines

9.

CAR T-Cell Therapy Epidemiology and Patient Population

10.

Patient Journey

11.

Key Endpoints in CAR T-Cell Therapy 

12.

CAR T-Cell Therapy Marketed Drugs

13.

CAR T-Cell Therapy Emerging Drugs

14.

7MM CAR T-Cell Therapy Market Analysis

15.

Market Access and Reimbursement

16.

KOL Views

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

CAR T-Cell Therapy Competitive Landscape

CAR T-cell Therapy Competitive Landscape – 2023 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others.

CAR T-Cell Therapy for Multiple Myeloma Market

CAR T-Cell Therapy for Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for multiple myeloma companies, including Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, among others.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for acute lymphoblastic leukemia companies, including Autolus, Pepromene Bio, Actinium Pharmaceuticals, among others.

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for non-Hodgkin's lymphoma companies, including Juno Therapeutics, Allogene Therapeutics, Caribou Biosciences, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com  
+91-9650213330
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging ...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.